{"id":45912,"date":"2025-11-05T21:58:13","date_gmt":"2025-11-05T13:58:13","guid":{"rendered":"https:\/\/flcube.com\/?p=45912"},"modified":"2025-11-05T21:58:14","modified_gmt":"2025-11-05T13:58:14","slug":"sichuan-biokin-secures-breakthrough-therapy-designation-for-her2%e2%80%91targeted-adc-t%e2%80%91bren","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45912","title":{"rendered":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China\u2019s <strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its proprietary antibody\u2011drug conjugate (ADC) <strong>T\u2011Bren<\/strong> received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the National Medical Products Administration (NMPA). The designation targets patients with <strong>HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma<\/strong> who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-t-bren-matters\">Why T\u2011Bren Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 T\u2011Bren combines a HER2\u2011specific monoclonal antibody with a potent cytotoxic payload, delivering targeted cell\u2011killing while sparing normal tissue.<\/li>\n\n\n\n<li><strong>Early\u2011Phase Efficacy<\/strong> \u2013 Interim results from Chinese cohorts show robust tumor shrinkage and durable disease control in heavily pre\u2011treated patients.<\/li>\n\n\n\n<li><strong>Best\u2011in\u2011Class Potential<\/strong> \u2013 The ADC\u2019s linker chemistry and payload design position it ahead of competing HER2\u2011ADC candidates on the market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-landscape\">Clinical Development Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Phase<\/th><th>Indication<\/th><th>Location<\/th><\/tr><\/thead><tbody><tr><td>Phase\u202fIII (5)<\/td><td>HER2\u2011positive gastric\/GEJ<\/td><td>China<\/td><\/tr><tr><td>Phase\u202fII\/III (1)<\/td><td>HER2\u2011positive gastric\/GEJ<\/td><td>Global<\/td><\/tr><tr><td>Phase\u202fII (2)<\/td><td>HER2\u2011positive breast, adjuvant, neoadjuvant, and HER2\u2011low breast cancer<\/td><td>China &amp; USA<\/td><\/tr><tr><td>Phase\u202fI\/II (3)<\/td><td>HER2\u2011mutated NSCLC, GI, GU, and gynecologic tumors<\/td><td>China\/International<\/td><\/tr><tr><td>Phase\u202fI (3)<\/td><td>Safety in early\u2011stage disease and oncology indications<\/td><td>China &amp; Overseas<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Biokin is currently enrolled in <strong>14 active clinical programs<\/strong> worldwide, the majority of which are phase\u202fIII or phase\u202fII\/III studies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-and-market-implications\">Regulatory and Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Review Pathway<\/strong> \u2013 BTD enables faster NMPA review and possible priority reimbursement by China\u2019s national immunization program.<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong> \u2013 With gastric cancer incidence exceeding 800,000 cases annually in China, T\u2011Bren could capture a sizeable slice of the <strong>HER2\u2011positive<\/strong> therapeutic niche, potentially generating <strong>>US$\u202f2\u202fbillion<\/strong> in sales by 2030 if successful.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 The company plans to license its ADC platform to global partners, leveraging its robust clinical portfolio and NMPA\u2019s BTD recognition to negotiate favorable co\u2011development terms.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context\">Competitive Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Development Stage<\/th><th>Key Differentiator<\/th><\/tr><\/thead><tbody><tr><td>Novartis (Enhertu)<\/td><td>T\u2011dem?<\/td><td>Phase\u202fIII<\/td><td>Conventional payload<\/td><\/tr><tr><td>Geron (T\u2011Tox)<\/td><td>HER2\u2011ADC<\/td><td>Phase\u202fII<\/td><td>Less stable linker<\/td><\/tr><tr><td><strong>Biokin (T\u2011Bren)<\/strong><\/td><td>HER2\u2011ADC<\/td><td><strong>BTD\u2011approved<\/strong><\/td><td>Linker\u2011payload innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA\u2019s BTD for T\u2011Bren places Sichuan Biokin in a strong position to outpace these rivals, particularly in the rapidly expanding gastric\u2011cancer ADC segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom\u2011Line<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The BTD marks a pivotal milestone for Sichuan Biokin, boosting confidence in T\u2011Bren\u2019s clinical trajectory and setting the stage for a high\u2011impact entry into China\u2019s HER2\u2011targeted oncology arena.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688506_20251105_AJEY.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20251105_AJEY.\"><\/object><a id=\"wp-block-file--media-c86e11fe-8703-4f26-9178-741fc6755fba\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688506_20251105_AJEY.pdf\">688506_20251105_AJEY<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688506_20251105_AJEY.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c86e11fe-8703-4f26-9178-741fc6755fba\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45914,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,151,16,857],"class_list":["post-45912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45912\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45912\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T13:58:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T13:58:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren\",\"datePublished\":\"2025-11-05T13:58:13+00:00\",\"dateModified\":\"2025-11-05T13:58:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912\"},\"wordCount\":414,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0504-1.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45912#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45912\",\"name\":\"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0504-1.webp\",\"datePublished\":\"2025-11-05T13:58:13+00:00\",\"dateModified\":\"2025-11-05T13:58:14+00:00\",\"description\":\"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45912\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0504-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0504-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45912#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45912","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren","og_description":"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.","og_url":"https:\/\/flcube.com\/?p=45912","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T13:58:13+00:00","article_modified_time":"2025-11-05T13:58:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45912#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45912"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren","datePublished":"2025-11-05T13:58:13+00:00","dateModified":"2025-11-05T13:58:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45912"},"wordCount":414,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45912#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45912#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45912","url":"https:\/\/flcube.com\/?p=45912","name":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45912#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45912#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","datePublished":"2025-11-05T13:58:13+00:00","dateModified":"2025-11-05T13:58:14+00:00","description":"China\u2019s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody\u2011drug conjugate (ADC) T\u2011Bren received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA). The designation targets patients with HER2\u2011positive locally advanced or metastatic gastric or gastro\u2011esophageal junction (GEJ) adenocarcinoma who have failed first\u2011line anti\u2011HER2 therapy and chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45912#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45912"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45912#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","width":1080,"height":608,"caption":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45912#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Secures Breakthrough Therapy Designation for HER2\u2011Targeted ADC T\u2011Bren"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0504-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45912"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45912\/revisions"}],"predecessor-version":[{"id":45915,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45912\/revisions\/45915"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45914"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}